Chemistry: analytical and immunological testing – Biological cellular material tested
Reexamination Certificate
1997-03-21
2001-04-24
Duffy, Patricia A. (Department: 1645)
Chemistry: analytical and immunological testing
Biological cellular material tested
C435S007100, C435S007210, C435S007900, C435S347000, C435S373000, C435S375000, C800S003000
Reexamination Certificate
active
06221670
ABSTRACT:
TECHNICAL FIELD
The present invention is in the field of assays used to identify agents for treating Alzheimer's disease. The present invention specifically provides methods for use in screening agents for use in reducing &bgr;-amyloid production/secretion/deposition, mainly in the treatment of Alzheimer's disease.
BACKGROUND ART
Alzheimer's disease (Alzheimer's) is a common age-related brain degenerative disease. The disease is characterized by progressive dementia together with the presence of characteristic neuropathological features. The formation of &bgr;-amyloid deposits or plaques is a hallmark and diagnostic feature of Alzheimer&bgr;s disease (Khachaturian (1985)
Arch Neurol
42:1097-1105). A significant body of evidence suggests that the process of &bgr;-amyloid formation and deposition is directly linked to the development of this disease. For example, individuals with mutations in the gene encoding the &bgr;-amyloid precursor protein (&bgr;-APP) invariably develop Alzheimer's disease (Goate et al.(1991)
Nature
353:844-846; Mullan et al. (1992)
Nature Genet
1:345-347; Murrell
et al.
(1991)
Science
254:97-99; Van Broeckhoven (1995)
Eur Neurol
35:8-19). The &bgr;-amyloid peptide is a 39-43 amino acid protein (Glenner et al. (1984)
Biochem Biophys Res Commun
120:885-890; Masters et al (1985)
Proc Natl Acad Sci USA
82:4245-4249) which is capable of forming &bgr;-pleated sheet aggregates. These aggregating fibrils are subsequently deposited in the brain parenchyma or in the cerebrovasculature of the Alzheimer's disease victim.
The &bgr;-amyloid peptide is derived from a larger Type I membrane spanning protein, &bgr;-APP, which has several alternatively spliced transcripts (Kang et al. (1987)
Nature
325:530-532; Ponte et al. (1988)
Nature
331:525-527; Tanzi et al. (1988)
Nature
331:528-530; Kitaguchi
el al.
(1988)
Nature
331: 530-532; de Savage et al (1989)
Science
245:651-653). The differentially spliced transcripts give rise to &bgr;-APP of 695, 714, 751, and 770 amino acids. The biological function of &bgr;-APP is not well understood although it appears to function in cell to cell contact, cell survival, and cell proliferation (Schubert
et al.
(1989)
Neuron
3:689-694; Saitoh et al. (1989)
Cell
58:615-622; Chen
et al.
(1991)
Neurosci Lett
125:223-251; Mattson et al. (1993)
Neuron
10:243-254).
A secreted form of &bgr;-APP is normally generated by proteolytic cleavage (Weidemann et al. (1989)
Cell
57:115-126). This proteolytic cleavage occurs within the &bgr;-amyloid domain precluding &bgr;-amyloid formation (Esch et al. (1990)
Science
248:1122-1124; Sisodia et al. (1990)
Science
248:492-495). As a result of the cleavage, the bulk of &bgr;-APP is released from the cell and a carboxyl terminal fragment of ~8 kDa remains bound to the cell membrane. The enzyme(s) responsible for this non-amyloidogenic processing of &bgr;-APP is termed &ggr;-secretase.
The formation of &bgr;-amyloid peptide is a normal physiological process. The peptide has been found to be naturally produced by cultured cells in vitro (Haass et al. (1992)
Nature
359:322-325; Seubert et al (1992)
Nature
359:325-327; Shoji et al. (1992)
Science
258:126-129; and in vivo (Seubert
et al. (
1992)
Nature
359:325-327; Vigo-Pelfrey et al. (1993)
J Neurochem
61:1965-1968; Tabaton et al. (1994)
Biochem Biophys Res Commun
200:1598-1603; Teller et al. (1996)
Nature Med
2:93-95). The &bgr;-amyloid peptide appears to be a degradation by-product of intracellular catabolism of the non-secreted form of &bgr;-APP (Higaki et al. (1995)
Neuron
14:651-659) and inhibiting its formation has no apparent deleterious consequences in vitro. There are two proteolytic processing steps required to produce the &bgr;-amyloid peptide: one produces the amino-terminus of the peptide mediated by an unidentified enzyme(s) referred to as &bgr;-secretase, the second forms the carboxyl-terminus of the peptide which is generated by an unidentified enyme(s) termed &ggr;-secretase.
Attention in the Alzheimer's disease research community has been directed to inhibiting the processing of &bgr;-APP into &bgr;-amyloid peptide as an approach to novel therapeutic development for Alzheimer's disease. Neither the &bgr;- nor &ggr;-secretase processing enzymes have been definitively identified or purified. No assay exists which contains pure &bgr;-APP and pure &bgr;-amyloid forming enzymes. Intact cultured cells provide a source of &bgr;-amyloid peptide. Screens for compounds which inhibit &bgr;-amyloid production have been developed based on measurement of &bgr;-amyloid production by cells in culture following application of a test compound. Toxicity of the compound is measured concomitantly. Test compounds which score as non-toxic inhibitors in such an assay are then tested for activity in animals. However, animal testing is laborious, expensive, and time consuming. In addition, many significant obstacles to obtaining inhibition of &bgr;-amyloid production in an animal exist which are absent in cell culture, including metabolism and clearance of the compound, limited access to the target organ (brain) imposed by the blood brain barrier, and selective cell toxicity. Thus, negative results in animal tests are difficult to interpret and are of limited use in informing structural design of other compounds. For these reasons it would be highly desirable to obtain a system for testing compounds for &bgr;-amyloid inhibiting activity and toxicity which resembled the complexity of the intact target organ, yet circumvented the technical difficulty of performing and interpreting whole animal testing experiments.
Organotypic slice culture methods have been developed for brain in which explants or sections of whole brain or, more commonly, a discrete anatomical brain structure such as hippocampus or cerebellum, are maintained in culture for extended periods of time (Seil (1979)
Review in Neuroscience
4:105-177; Gahwiler (1981)
J. Neurosci Meth
4:329-342; Gahwiler (1984)
Neuroscience
11:751-760, Gahwiler (1988)
Trends Neurosci
11:484-490). Recently significant improvements have been developed such that more reproducible results may be obtained through a simplified method (Stoppini et al., (1991)
J Neurosci Methods
37:173-182). An essential feature of such cultures is the striking preservation of organotypic tissue architecture: cellular anatomy closely resembles that in the intact brain, to the extent that synaptic inputs and function mimic that of the normal situation, and development continues in neonatal brain slices. Typically, these preparations are used for electrophysiological studies investigating brain phenomena such as the biochemical basis of learning which require complex interactions of cells available only in the intact animal or organotypic slice cultures. Only two examples of use of organotypic brain slice cultures in Alzheimer's disease research are known in the art. London et al. ((1996)
Proc Natl Acad Sci
93:4147-4153) looked at interactions of different brain cell types by applying monocytes pre-treated with synthetic amyloid to organotypic brain slice cultures, measuring cell survival. Nitsch, Wurtzman, and colleagues have examined the effects of neural stimulation by electrodes and neurotransmitters on brain circuitry (Diekman et al. (1994)
J Neural Transm Suppl
44:61-71) and secretion of amyloid precursor protein (Nitsch et al (1994)
J Neural Transm Suppl
44:21-27); Farber et al. (1995)
J Neurosci
15:7442-7451).
The organotypic slice culture method has not been combined with assays for &bgr;-amyloid and cell viability to examine amyloid production and/or the effect of test compounds on its production. The present invention is based, in part, on combining organotypic slice culture methods with &bgr;-amyloid assays methods. The resulting methods of the present invention provides a rapid and efficient method for identifying compounds that can be used to treat Alzeimer's.
Prior art for testing compounds for inhibition of &bgr;
Cordell Barbara
Higgins Linda Slanec
Duffy Patricia A.
Morrison & Foerster / LLP
Scios Inc.
LandOfFree
Methods to identify &bgr;-amyloid reducing agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to identify &bgr;-amyloid reducing agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to identify &bgr;-amyloid reducing agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2501368